LivingGLP1
Descriptive only

Systolic blood pressure change

Overweight or obesity without diabetes (adults)

weeks 40 to 104 (target week 68)While on treatmentEach dose separatelyMean difference
1
Randomized trials
5
Treatments
381
Participants
5
Trial arms

In plain language

No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 1 trial. The trial data below are shown as reported.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
PLACEBOSURV_SC_0p6MG_QWSURV_SC_2p4MG_QWSURV_SC_3p6MG_QWSURV_SC_4p8MG_QW
Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
Baseline effect modifiers and prognostic factors per trial
TrialBaseline BMI or body weight (kg/m2)
effect modifier, prognostic factor; 0 of 1
NCT04667377
S002375
body weight 105.7 kg

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
  • FlagBaseline, Baseline BMI or body weight: not reported by 1 of 1 trials
Comparability items per trial
Trialtime weeksanalysis setdefinitioninstrumentadjudicatedproportion methodintercurrent events (discontinuation)intercurrent events (rescue)blindingfundingstart yearEligibility
NCT0466737746full_analysischange in systolic blood pressure from baselinenot statednot statednot statednot statednot stateddouble_blindindustry2021age 18 to under 75; BMI 27 or more; HbA1c below 6.5 percent; weight 70 kg women or 80 kg men or more

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the mean difference on the analysis scale against the trial's first row. Flags mark converted, combined or approximated inputs.
Trial data entering this analysis
TrialArmTreatmentWeekDataValueSEEvents / NFlagsSource
NCT04667377A1SURV_SC_0p6MG_QW46arm, change-6.1901.47075registry:outcomes
NCT04667377A2SURV_SC_2p4MG_QW46arm, change-8.0801.48078registry:outcomes
NCT04667377A3SURV_SC_3p6MG_QW46arm, change-8.6601.44076registry:outcomes
NCT04667377A4SURV_SC_4p8MG_QW46arm, change-8.6201.46076registry:outcomes
NCT04667377A5PLACEBO46arm, change-2.4601.46076registry:outcomes

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab